"Post-procedure repair" is one of the fastest-growing and most frequently mis-filed categories in beauty. The products look like sheet masks, they are sold next to serums, and they are marketed in the language of recovery. Regulators read them completely differently — and the word that decides everything is intended use.
If you are building a post-laser, post-microneedling, post-peel or post-injection aftercare line, you are standing on one of the sharpest regulatory boundaries in the industry. On one side: a cosmetic, regulated as a cosmetic, cheap and fast to launch. On the other: a medical device, with a quality system, a technical file, a conformity route and — in the EU — a notified body. This guide maps that boundary for the US, EU, UK and Australia, and shows you how to qualify a factory without being sold a story.
The line that decides everything: cosmetic or device
Both regimes classify on intended use, and they infer intended use from your claims, your labelling, your instructions for use and your marketing — not from what you call it internally.
The pattern is unambiguous. Once the product is intended for skin that is no longer intact, or is claimed to manage a wound, you have left cosmetics. A cosmetic is applied to healthy skin; the moment your intended use becomes a wound, the word "repair" stops being marketing and becomes a regulated function.
Two specific traps:
- Ablative procedures breach the dermis. After fully ablative resurfacing, the skin is an open wound. Anything you place on it with a therapeutic purpose is a device, not a cream.
- "Post-procedure" is not a safe word by itself. If the skin is intact (after a mild peel, LED, or a non-ablative pass) and you claim only cooling, soothing and moisturising, a cosmetic positioning can hold. If the same carton says "accelerates healing" or "for post-treatment wounds", it does not.
What "post-procedure" actually means to your regulator
United States. Under the FD&C Act, a product intended to diagnose, cure, mitigate, treat or prevent disease — or to affect the structure or any function of the body — is a drug or a device. Cosmetics are limited to cleansing, beautifying, promoting attractiveness and altering appearance. Promoting wound healing affects the structure and function of the body, so it is out of cosmetic scope. FDA has issued warning letters for exactly this: aftercare products sold as cosmetics while claiming to treat wounds.
European Union. Regulation 1223/2009 defines a cosmetic by its functions — cleaning, perfuming, changing appearance, protecting, keeping in good condition, correcting body odours. A product with a pharmacological, immunological or metabolic action, or one presented as treating a condition, becomes a medicinal product under Directive 2001/83/EC. A wound dressing whose principal intended action is physical (a barrier, a moist environment, exudate management) is a medical device under Regulation (EU) 2017/745. The distinction between device and medicine depends on whether the principal intended action is physical or pharmacological.
United Kingdom. Great Britain retains a UK version of the EU device rules, with a UK Responsible Person and UKCA conformity marking for devices placed on the GB market; devices are registered with the MHRA. Northern Ireland continues to follow the EU MDR route with CE/UKNI marking.
Australia. Therapeutic goods are regulated by the TGA. Wound dressings are generally included in the ARTG; sterile dressings and those with antimicrobial claims sit in higher risk classes. A cosmetic claim set keeps you out of the therapeutic sphere — a healing claim puts you in it.
The US path: FDA device classification and 510(k)
Most wound dressings in the US are Class I (often 510(k)-exempt) or Class II (510(k) required). The distinction turns on intended use and technology:
A 510(k) programme realistically runs 6–12 months including predicate selection, performance testing and FDA's review cycle, with a standard review fee in the low tens of thousands of US dollars and a reduced small-business rate. Add establishment registration and device listing (annual), a US Agent if the manufacturer is foreign, and biocompatibility testing against the ISO 10993 series for anything contacting breached skin or a wound.
If you want to launch in 90 days, do not design a device. Design a cosmetic that stays inside cosmetic claims and let a separate, properly filed device SKU come later.
The EU path: MDR 2017/745 classification and CE marking
Under MDR Annex VIII, classification for devices contacting injured skin follows a well-established ladder:
Note what this means commercially: the "medical device" stickers that appear on imported sheet masks almost never correspond to a CE-marked Class IIa device with a notified body behind them. When a supplier offers a "medical-grade" mask at cosmetic lead times and cosmetic prices, ask which conformity route was used and which notified body number appears on the label. If there is no four-digit notified body number, there is no CE marking under MDR for a Class IIa device.
The technical file for a device is not a PIF. It requires device description and specifications, classification rationale, general safety and performance requirements mapping, risk management (ISO 14971), biocompatibility (ISO 10993), sterilisation validation (ISO 11135/11137) if sterile, shelf-life validation, clinical evaluation or equivalence argument, and post-market surveillance with vigilance reporting.
Factory qualification: ISO 13485, not ISO 22716
This is the qualification error that costs buyers the most money. Cosmetic GMP is ISO 22716 (or a national GMPC scheme). Medical device quality management is ISO 13485. They are not interchangeable, and a factory holding only ISO 22716 is not qualified to manufacture devices in any of these markets.
Ask for the scope statement on the ISO 13485 certificate, not just the logo. Plenty of certificates cover "design and manufacture of non-sterile wound dressings" and nothing else.
Claim red lines: the phrases that get products pulled
- "Medical grade", "clinical grade", "hospital grade" — in the US this implies a regulatory status you do not have and is a favourite NAD and class-action target. In the EU, suggesting a medicinal or certified status on a cosmetic is equally problematic.
- "Heals", "repairs skin damage", "accelerates recovery" — these are therapeutic claims. On a cosmetic they are out of scope; on a device they must be inside the cleared intended use.
- "Sterile" on a product made without terminal sterilisation and validation — false.
- "Antimicrobial", "antibacterial" — in the EU this can also trigger the Biocidal Products Regulation; in the US it can push a cosmetic into OTC drug territory.
- "For use on broken skin" on a cosmetic — self-incriminating. Cosmetics are for intact skin.
The safe cosmetic vocabulary is narrow and it works: cools, soothes, hydrates, helps comfort skin, supports the skin's moisture barrier, suitable for use after non-invasive treatments. Note what is missing: verbs that promise a biological outcome.
MOQ, cost and timeline
Device routes carry a 20–50% unit cost premium over a cosmetic equivalent. That premium is cleanroom time, batch documentation, validation runs and vigilance overhead. A quote that removes the premium has usually removed the work.
FAQ
My clinic wants an aftercare mask. Do I need a device?
Only if you claim it for non-intact skin or a wound purpose. Most clinics can launch a compliant cosmetic aftercare mask first and file a device later once volume justifies it.
Can a factory make both my cosmetic and my device in one plant?
Sometimes, under a documented dual quality system. In practice the device line needs its own cleanroom, its own batch records and its own change-control procedure. Treat it as a separate facility inside the same building.
Is "medical device" printed on a Chinese mask meaningful in the US?
Not by itself. It refers to a Chinese registration category. It does not substitute for FDA establishment registration, device listing and, where applicable, 510(k) clearance. The mapping must be done again for each market.
How long does ISO 13485 certification take a factory?
Meaningfully longer than ISO 22716: typically 6–12 months of documented QMS operation before a certification audit, and the scope has to match your product.
What if my product contains an active that works pharmacologically?
Then the principal intended action is pharmacological and, in the EU, you are likely looking at a medicinal product rather than a device. Get a regulatory opinion before you commit to tooling.
🔗 Where QuickOEM fits. Tell us the intended use first and we will route your brief to the right factory tier: ISO 22716/GMPC plants for cosmetic aftercare (MOQ 1,000–3,000 units, sampling in 7–15 days), and ISO 13485 device plants with cleanroom validation, ISO 10993 biocompatibility packages and export registration experience for device programmes. We pre-check certificates against scope, not logos, and we flag claim language that would pull a cosmetic SKU into device territory before your artwork goes to print. → https://www.quickoem.com/en/contact